SPARC · Sun Pharma Advanced Research Company Limited · Financials
Volume · Nov 13
130.25K
Avg daily vol (3M)
101.82K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Revenue
18.79B
+2518.3%
FY2026
Net Income
15.56B
+554%
FY2026
Operating Cash Flow
-2.39B
+33.7%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 |
|---|---|---|---|---|
| INR | 19.32B | 18.79B | 717.7M | 755.5M |
| INR | 93.7M | 102.1M | 123.9M | 125.1M |
| INR | 286.7M | 341.3M | 90.4M | 16.9M |
| INR | 16.36B | 15.53B | -3.43B | -3.87B |
| INR | -1.2M | -1.9M | -2.7M | 3.8M |
| INR | 16.36B | 15.56B | -3.43B | -3.87B |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2026: 0 in dividends.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.